WBWenkun Bai

Wenkun Bai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenkun Bai has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Xiao Li

    Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Junyi Ren

    Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Lianjie Sun

    Qingdao University, Qingdao, China

    3 shared publications
  • Wen Li

    Department of Ultrasound, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Ying Xu

    Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Yuanyi Zheng

    Department of Ultrasound in Medicine, Shanghai Sixth People ’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China

    3 shared publications

Latest Publications

  • Open Access

    Methodology exploration and reproducibility evaluation of TAI and TSI for quantitative ultrasound assessment of hepatic steatosis

    by Xiao Li, Ziwei Sun, Wei Liu, Lianjie Sun, Junyi Ren, Ying Xu, Haoyong Yu, Wenkun Bai


  • Open Access

    Efficacy of low-intensity pulsed ultrasound in the treatment of COVID-19 pneumonia

    by Wen Li, Xiao Li, Zhibin Kong, Bin Chen, Hongsheng Zhou, Yimin Jiang, Weimei Li, Lichang Zhong, Xinyu Zhang, Kaihua Zhang, et al.

    Purpose As a public health emergency of international concern, coronavirus disease 2019 (COVID-19) still lacks specific antiviral drugs, and symptomatic treatment is currently the mainstay. The overactivated inflammatory response in COVID-19 patients is associated with a high risk of critical illness or even death. Low-intensity pulsed ultrasound (LIPUS) can mitigate inflammation and inhibit edema formation. We aimed to investigate the efficacy of LIPUS therapy for COVID-19 pneumonia. Materials and Methods 62 patients were randomly assigned to a treatment group (LIPUS treatment area – Group 1; self-control area – Group 2) and an external control group (Group 3). The primary outcomes were the volume absorption rate (VAR) and the area absorption rate (AAR) of lung inflammation in CT images. Results After an average duration of treatment 7.2 days, there were significant differences in AAR and VAR between Group 1 and Group 2 (AAR 0.25 vs 0.12, p=0.013; VAR 0.35 vs 0.11, p=0.005), and between Group 1 and Group 3 (AAR 0.25 vs 0.11, p=0.047; VAR 0.35 vs 0.19, p=0.042). Neither AAR nor VAR was statistically different between Group 2 and Group 3. After treatment, C-reactive protein, interleukin-6, leukocyte, and fingertip arterial oxygen saturation (SaO2) improved in Group 1, while in Group 3 only fingertip SaO2 increased. Conclusion LIPUS therapy reduced lung inflammation and serum inflammatory factor levels in hospitalized COVID-19 patients, which might be a major advancement in COVID-19 pneumonia therapy.


  • Open Access

    Efficacy of low-intensity pulsed ultrasound for the treatment of viral pneumonia: study protocol for a randomized controlled trial

    by Xiao Li, Wen Li, Lianjie Sun, Junyi Ren, Ying Xu, Yuanyi Zheng, Wenkun Bai

    Background: Viral pneumonia has always been a problem faced by clinicians because of its insidious onset, strong infectivity, and lack of effective drugs. Patients with advanced age or underlying diseases may experience more severe symptoms and are prone to severe ventilation dysfunction. Reducing pulmonary inflammation and improving clinical symptoms is the focus of current treatment. Low-intensity pulsed ultrasound (LIPUS) can mitigate inflammation and inhibit edema formation. We aimed to investigate the efficacy of therapeutic LIPUS in improving lung inflammation in hospitalized patients with viral pneumonia. Methods: Sixty eligible participants with clinically confirmed viral pneumonia will be assigned to either (1) intervention group (LIPUS stimulus), (2) control group (null stimulus), or (3) self-control group (LIPUS stimulated areas versus non-stimulated areas). The primary outcome will be the difference in the extent of absorption and dissipation of lung inflammation on computed tomography. Secondary outcomes include changes in lung inflammation on ultrasonography images, pulmonary function, blood gas analysis, fingertip arterial oxygen saturation, serum inflammatory factor levels, the sputum excretion volume, time to the disappearance of pulmonary rales, pneumonia status score, and course of pneumonia. Adverse events will be recorded. Discussion: This study is the first clinical study of the efficacy of therapeutic LIPUS in the treatment of viral pneumonia. Given that the current clinical recovery mainly depends on the body’s self-limiting and conventional symptomatic treatment, LIPUS, as a new therapy method, might be a major advance in the treatment of viral pneumonia. Trial registration: ChiCTR2200059550 Chinese Clinical Trial Registry, May 3, 2022.


  • Open Access

    Effectiveness of low-intensity pulsed ultrasound for the treatment of viral pneumonia: study protocol for a prospective, randomized controlled trial

    by Xiao Li, Wen Li, Lianjie Sun, Junyi Ren, Ying Xu, Yuanyi Zheng, Wenkun Bai

    Background: Viral pneumonia has always been a problem faced by clinicians because of its insidious onset, strong infectivity and lack of effective drugs. Patients with advanced age or underlying diseases may experience more severe symptoms and are prone to severe ventilation dysfunction. Reducing pulmonary inflammation and improving clinical symptoms is the focus of current treatment. Low-intensity pulsed ultrasound (LIPUS) can mitigate inflammation and inhibit edema formation. We aimed to investigate the effectiveness of therapeutic LIPUS in improving lung inflammation in hospitalized patients with viral pneumonia. Methods: This study protocol entails a prospective, randomized controlled trial. 60 eligible participants with clinically confirmed viral pneumoniawill be assigned to either (1) test group (LIPUS stimulus), (2) external control group (null stimulus), or (3) self-control group (LIPUS stimulated areas versus non-stimulated areas). The primary outcome will be the difference in the extent of absorption and dissipation of lung inflammation on computed tomography andultrasonography images. Secondary outcomes include pulmonary function, blood gas analysis, fingertip arterial oxygen saturation, serum inflammatory factor levels, the sputum excretion volume, time to the disappearance of pulmonary rales, pneumonia status score, and course of pneumonia. Adverse events will be recorded. Intention-to-treat analyses will be used. Discussion: This study is the first clinical study of the effectiveness of therapeutic LIPUS in the treatment of viral pneumonia. Given that the current clinical recovery mainly depends on the body's self-limiting and conventional symptomatic treatment, LIPUS, as a new therapy method, might be a major advance in the treatment of viral pneumonia. Trial registration: ChiCTR2200059550 Chinese Clinical Trial Registry

  • Open Access

    Marriage of Virus‐Mimic Surface Topology and Microbubble‐Assisted Ultrasound for Enhanced Intratumor Accumulation and Improved Cancer Theranostics

    by Zheying Meng, Yang Zhang, E Shen, Wei Li, Yanjie Wang, Krishnan Sathiyamoorthy, Wei Gao, Michael C. Kolios, Wenkun Bai, Bing Hu, et al.

    The low delivery efficiency of nanoparticles to solid tumors greatly reduces the therapeutic efficacy and safety which is closely related to low permeability and poor distribution at tumor sites. In this work, an “intrinsic plus extrinsic superiority” administration strategy is proposed to dramatically enhance the mean delivery efficiency of nanoparticles in prostate cancer to 6.84% of injected dose, compared to 1.42% as the maximum in prostate cancer in the previously reported study. Specifically, the intrinsic superiority refers to the virus‐mimic surface topology of the nanoparticles for enhanced nano–bio interactions. Meanwhile, the extrinsic stimuli of microbubble‐assisted low‐frequency ultrasound is to enhance permeability of biological barriers and improve intratumor distribution. The enhanced intratumor enrichment can be verified by photoacoustic resonance imaging, fluorescence imaging, and magnetic resonance imaging in this multifunctional nanoplatform, which also facilitates excellent anticancer effect of photothermal treatment, photodynamic treatment, and sonodynamic treatment via combined laser and ultrasound irradiation. This study confirms the significant advance in nanoparticle accumulation in multiple tumor models, which provides an innovative delivery paradigm to improve intratumor accumulation of nanotherapeutics.


  • Open Access

    Post-traumatic adrenal hematoma: A case report and revue of literature

    by Y. Fadil, W. Bai, Y. Chakir, M. Dakir, A. Debbagh, R. Aboutaieb


  • Open Access

    The correlation between the gleason score of the biopsy and that of the prostatectomy patch

    by W. Bai, Y. Fadil, O. Idrissi, M. Dakir, A. Debbagh, R. Abouteib

    Since the advent of massive dosage of prostate specific antigen (PSA), prostate cancer has become a major public health problem. It is currently the most common cancer and the second leading cause of cancer death in men (after lung cancer). More than 670,000 new cases are diagnosed annually worldwide. This is a retrospective study including all patients treated for prostate cancer by radical prostatectomy at the Ibn Rochde University Hospital in Casablanca between January 2017 and December 2020, i.e. a period of 4 years. At the end of our study, we identified 18 cases of radical prostatectomy.


  • Open Access

    Inhibitory effects of subcutaneous tumors in nude mice mediated by low-frequency ultrasound and microbubbles

    by Zhi-Yong Shen, E. Shen, Xue-Hong Diao, Wen-Kun Bai, Min-Xia Zeng, Yan Yan Luan, Shu-Liang Nan, Yan-Duan Lin, Cong Wei, Li Chen, et al.

    The aim of the present study was to investigate the sonication effects of 21‑kHz ultrasound (US) with microbubbles (MBs) on the subcutaneous prostate tumors of nude mice. In total, 15 tumor‑bearing nude mice were divided into three groups: The control group, the low‑frequency US group and the US+MB group. The MBs used were from US contrast agent SonoVue. The parameters of the US were as follows: 21 kHz, 26 mW/cm2 and a 40% duty cycle (2 sec on, 3 sec off) for 3 min, once every other day for 2 weeks. Color Doppler flow imaging, hematoxylin and eosin (HE) staining, immunoblotting and transmission electron microscopy (TEM) were used to evaluate the results. Following 2 weeks of treatment, the blood flow signal disappeared in the US+MB group only, and the tumor size was smaller when compared with the control and US groups. For the immunoblotting, the intensity of cyclooxygenase‑2 and vascular endothelial growth factor in the US+MB group was lower compared with the other two groups. Tumor necrosis was present and the nucleus disappeared upon HE staining in the US+MB group. Upon TEM analysis, increased cytoplasmic vacuolation and dilatation of the perinuclear cisternae of the tumor cells were found in the US+MB group. In the control and US groups, the tumors had intact vascular endothelia and vessel lumens. However, lumen occlusion of the vessels was observed in the US+MB group. In conclusion, 21‑kHz low‑intensity US with MBs may result in vessel occlusion and growth inhibitory effects in the subcutaneous tumors of nude mice.